

Table of Contents

Preface	vii
About the Editors-in-Chief	viii

OVERVIEW OF BIOTHERAPIES AND REGULATORY CONSIDERATIONS

Section Editor: Ellen F. Lazarus, MD, ELS

1. The Growth and Development of Biotherapies 1

David Stroncek, MD, and David H. McKenna, Jr, MD, CABP(H)(AABB)

Biotherapies: The Early Years	1
Types of Cellular Therapies	2
Development of Cell Processing Centers	2
Elements of a Cell Processing Center	3
Manufacturing Cellular Therapies	5
Handling Commercial Cell Therapies	6
Conclusions	7
References	7

2. US Regulatory Considerations for Tissue and Cell and Gene Therapy Products 9

Vaibhav Patel, MS

Historical Evolution of FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products	10
FDA Regulatory Framework for HCT/Ps	11
Future Directions: Regulatory Flexibility and Innovation in CGT	26
Standards Recognition Program for Regenerative Medicine Therapies	30
Conclusion	33
References	33

SECTION 2: CELLULAR THERAPY QUALITY OVERSIGHT

Section Editor: J. Wade Atkins, MS, MLS(ASCP)SBB, CQA(ASQ), CABP(H)(AABB)

3. Approaches to Quality in Cellular Therapy Programs 37

J. Wade Atkins, MS, MLS(ASCP)SBB, CQA(ASQ), CABP(H)(AABB)

Fundamental Concepts of Quality Systems	38
Quality Methods	38
Areas of Focus	39
Conclusion	40
References	40

4. Providing a Functional Quality Approach in Cell Therapy 41

Deborah L. Griffin, MSc, ASQ CPGP

Establishing a Functional Approach to Quality	41
Quality: Roles and Responsibilities	42
Critical Elements for Success	43
Conclusion	52
References	52

5. Process Improvement 53

Jessica Sue, MHSM

Proactive Identification of Opportunities	53
Regulatory Change	54
Errors and Near-Miss Events	55
Complaints	56
Root Cause Analysis	57
Corrective/Preventive Action	62
Conclusion	65
References	66

6. Quality Management Support for Operations 69

Deborah L. Griffin, MSc, ASQ CPGP

Research and Development	69
Process Design	70
Sustained Process Control	72
Chain of Identity and Chain of Custody	72
Qualifications, Validations, and Verifications	73
Policies, Processes, and Procedures	79
Conclusion	80
References	81

7. Quality Support for Manufacturing83

Phillip Johnson, MMedSc(Path)

Materials Management	83
Facilities Management	85
Environmental Monitoring	86
Conclusion	89

8. Chain of Identity (COI) and Chain of Custody (COC) for Cellular Therapy Products91

Deborah L. Griffin, MSc, ASQ CPGP

COI and COC in Accreditation Standards and Regulatory Requirements	91
Establishment and Maintenance of COI and COC for Cellular Therapy Products ...	93
Documenting COI and COC	100
Assessment of the Robustness of COI and COC	100
Conclusion	101
References	101
Appendix 8-1. Template for Assessment of COI/COC	103
Appendix 8-2. Example of Completed Assessment of COI/COC for Autologous Product with a Short-Term Refrigerated Hold	104

9. Product Testing and Characterization 107

Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)

Product Attributes	107
Assay Selection	112
Record Review	113
Summary	113
References	113

10. Batch Release Records and Record Retention 115

*Brenda Alder, MS, MLS(ASCP)SBB, CABP(H)(AABB), and
Sarah Powell, MLS(ASCP)MPH*

Document Management and Traceability	115
Record Creation	117
Storage, Security, and Best Practices for Records	118
Definition of Terms	121
References	122

11. Pulling It All Together 123

J. Wade Atkins, MS, MLS(ASCP)SBB, CQA(ASQ), CABP(H)(AABB)

Accreditation Standards	123
Key Points for Quality in Biotherapies	128
References	128

SECTION 3: CELL PROCESSING OPERATIONS, FACILITIES, AND EQUIPMENT

Section Editor: Diane Kadidlo, MT(ASCP), SBB

12. Personnel: Hiring, Training, and Competency 129

*Tumari Tutt and Mary Grable McLeod, MLS(ASCP)^{CM}SBB^{CM}, SSGb(ASQ),
CABP(H)(AABB)*

Hiring Staff	129
Training and Competency Program Development	133
Systems and Methods/Modalities	134
Training and Competency Program in Practice	138
Conclusion	139
References	140
Appendix 12-1. Example Training Plan for a New Hire (Technologist)	142
Appendix 12-2. Example Training Module	143
Appendix 12-3. Example Competency Plan	145
Appendix 12-4. Example Competency Module	146
Appendix 12-5. Example of a Training Matrix	148
Appendix 12-6. Example of a Competency Matrix	149

13. General Considerations for Facility Operations 151

Christina Vaughan, MS, CABP(AABB), and Emily Hopewell, PhD, CABP(H)(AABB)

Facility Design Considerations	151
Qualification and Commissioning	159
Aseptic Processing and Monitoring of Facility Critical Parameters	159
Final Summary	169
References	170

14. Equipment and Supplies 171

Mary Grable McLeod, MLS(ASCP)^{CM}SBB^{CM}, SSGb(ASQ), CABP(H)(AABB)

Equipment Management	171
Supply Management	178
Summary	181
References	181

SECTION 4: CELL COLLECTION

Section Editors: David Stroncek, MD, and David H. McKenna, Jr, MD, CABP(H)(AABB)

15. Autologous and Allogeneic Donor Qualification 183

*Jensyn K. Cone Sullivan, MD, CABP(AABB), and Suzanne R. Thibodeaux,
MD, PhD, CABP(H)(AABB)*

Donor Recruitment and Informed Consent	183
Donor Medical Suitability	185
Donor Eligibility	186
Regulatory and Legal Framework	188
Accreditation and Quality Considerations	189
Requirements for Commercial Products	190
Conclusion	192
References	192

16. Collection of Starting Materials for Cellular Therapies 195

Monika Paroder, MD, PhD, and Joseph Schwartz, MD, MPH, CABP(AABB), QIA

Overview of Therapies	195
Cell Collections	203
Product Labeling, Chain of Custody, and Chain of Identity	218
Summary	219
References	219

SECTION 5: MANUFACTURING CELLULAR THERAPIES

Section Editors: David Stroncek, MD, and David H. McKenna, Jr, MD, CABP(H)(AABB)

17. Manufacturing: General Considerations 227

Beth Shaz, MD, MBA, and Brian R. Shy, MD, PhD

Human Cells, Tissues, and Cellular and Tissue-Based Products	227
Manufacturing Models	230
Facility Design	233
Manufacturing Process	235
Materials and Supply Chain Management	242
Process Development and Validation	245
Analytical Testing and Quality Control	249
Quality Assurance and Quality Management Systems	251
Risk Management and Mitigation	252
Future Directions and Conclusions	254
References	254

18. Product Development 259

Steven L. Highfill, PhD

Preclinical Synergy: Tech Transfer from the Preclinical Laboratory to GMP Product Development	259
Tech Transfer from GMP Product Development to GMP Manufacturing	261
Automation and Closed Systems	262
CMC Preparation	263
PD Evaluation of New Instruments, Material, and Reagents	263
Troubleshooting Clinical Manufacturing	264

Conclusions	264
References	265
19. Hematopoietic Stem Cell Processing	267
<i>Margaret Jones DiGuardo, MD; Monica Sung Klein, MD;</i>	
<i>Dustin James Strasburg, MLS(ASCP)^{CM}; Shannon Rose Strader, DO; and</i>	
<i>Eapen K. Jacob, MD</i>	
Types of Hematopoietic Progenitor Cell Products	267
Products Intended for Fresh Infusion	268
Cryopreservation	269
Fresh Infusions vs Cryopreservation	270
Overnight Processing	271
Special Processing Techniques	271
References	275
20. Manufacturing Advanced Cell and Gene Therapy	
Products/IND Products	279
<i>Jay Tanna, MS, RAC, and Patrick J. Hanley, PhD</i>	
Equipment Variability Across Product Types	280
Process Variability Across Product Types	280
Technology Transfer	283
Manufacturing Autologous Products vs Allogeneic Products	289
Material, People, and Product Flow Mapping	290
Conclusion	291
References	291
21. Manufacturing of Regenerative Cell Therapies Leveraging	
Biomaterials to Mimic Extracellular Matrix	295
<i>Magali J. Fontaine, MD, PhD; Brendyn Miller, PhD; Justine R. Yu, MD, PhD;</i>	
<i>and Anthony Atala, MD</i>	
Key Concepts in Developing Cell-Matrix Composites	296
Design Considerations for Developing Cell-Matrix Composites	298
Decellularized ECM as a Platform for Organ Regeneration	301
Drawbacks, Current Limitations, and Future Perspectives	309
Conclusions	311
References	312
22. Technologies in Biotherapeutics Manufacturing	317
<i>Andrew D. Fesnak, MD</i>	
General Principles	317
Isolation of the Target Starting Cell Type	319
Activation, Modification, and Expansion of Therapeutic Cells	321
Cell Washing, Harvest, Formulation, and Fill	324
Multifunction Equipment	325

Conclusions	326
References	326

SECTION 6: TESTING AND CHARACTERIZATION OF CELLULAR THERAPIES

Section Editor: Ena Wang, MD, MS

23. Requirements for Drug Release Testing 329

*Priya Balasubramanian, PhD; Jason Bock, PhD; Katrina Adlerz, PhD;
Cathy Wang, PhD; and Jiwen Chen, PhD*

General Considerations	330
Safety, Identity, Stability, Purity, and Potency	330
Distinctions Regarding Autologous vs Allogeneic Products	339
Master Cell Banks vs Working Cell Banks vs Final Product	340
Summary	341
References	342

24. Cell Therapy Product Characterization 343

Therese Choquette, PhD

Cell Product Characterization vs Product Release Testing	343
The Rationale for Cell Therapy Product Characterization	343
Time for Initiating Characterization	344
Sample Characterization	345
In-Vitro Functional Assays	349
Other Types of Characterization	353
Characterization Assays for iPSCs and hESCs	359
Summary	359
References	362

25. Stability Assessment: A Holistic Approach 367

*Don Fink, PhD; Liz Cauldwell, BS; Anne Lamontagne, MS; and
Melissa Triggiano, MS*

Applicable US FDA Regulations and Guidance Pertaining to Stability	367
Two Stability Assessment Manufacturing Scenarios	368
Stability Considerations: Manufacturing Process Physical Impacts	381
Stability: Key Takeaways	383
References	384

26. Potency Tests for Cell Therapy Products 387

Carl G. Simon, Jr, PhD

Overview of Potency Tests	387
Framework for Understanding Potency and Efficacy	388
Trends in Potency Tests for CTPs	390

Summary	397
References	397
27. Phase-Based Potency Assays	401
<i>Therese Choquette, PhD</i>	
Basics	401
Examples of Potency Assays	403
Summary	407
References	408
28. Assay Development	409
<i>Priya Balasubramanian, PhD; Katrina Adlerz, PhD; and Cathy Wang, PhD</i>	
Cell Count and Viability	410
Phenotype by Flow Cytometry	412
Molecular Assays, Including VCN and RCR	414
Qualification, Validation, and Tech Transfer	419
Conclusion	419
References	419
SECTION 7: LABORATORY ASSAYS COMMONLY USED TO EVALUATE CELLULAR THERAPIES	
<i>Section Editor: Ena Wang, MD, MS</i>	
29. Cell Counting in Cellular Therapies	421
<i>Yihua Cai, MD, PhD, and Ping Jin, MSc, PhD</i>	
Importance of Cell Counting in Cellular Therapy	421
Cell Counting Methods	422
Cell Counting in Specific Cellular Therapies	422
Challenges in Cell Counting for Cellular Therapy	423
Conclusions	423
References	424
30. Flow Cytometry Assays for Cellular Therapies	427
<i>Yihua Cai, MD, PhD; Kyu Lee Han, PhD; and Ping Jin, MSc, PhD</i>	
Overview	427
The Application of Flow Cytometry Assay in Hematopoietic Stem Cell Transplantation	437
Flow Cytometry Assay for CAR or TCR T-Cell Therapy	439
High-Dimensional Flow Cytometry Analysis by Full-Spectrum Flow Cytometer for the Advancement of Cell Therapy Research	444

Summary	447
References	447
Appendix 30-1. Example Spectral Flow Cytometry Acquisition Workflow (Cytex Platforms)	452
31. Metabolic Assays for Cellular Therapies	453
<i>Michaela Prochazkova, PhD, and Ping Jin, MSc, PhD</i>	
Extracellular Flux Assay	453
Live-Cell Metabolism Assay	462
Single-Cell Energetic Metabolism	462
Fluorescent Dyes	463
Luminescent Assays	466
Colorimetric Assays	467
Conclusion	467
References	468
32. Molecular Assays and Their Role in Cellular Therapies	471
<i>Jinxia Ma, PhD; Lipei Shao, PhD; and Ping Jin, MSc, PhD</i>	
Types of Molecular Assays	471
Molecular Assays for Cell Therapy Product Lot Release	475
Conclusion	479
References	480
SECTION 8: PRODUCT STORAGE, ISSUE, AND INFUSION	
<i>Section Editors: David Stroncek, MD, and David H. McKenna, Jr, MD, CABP(H)/(AABB)</i>	
33. Biopreservation	483
<i>Richa Kaushal, PhD; Akshat S. Mallya, MS; and Allison Hubel, PhD</i>	
Liquid Storage	484
Cryopreservation	485
Summary	496
References	496
34. Biotherapy Product Issuing and Infusion	501
<i>Wen Lu, MD</i>	
Fresh vs Cryopreserved Products	501
Thawing	502
Release	503
Infusion	504
Infusion Reactions	505
Summary	507
References	507

35. Off-Site Manufactured Cell Therapy Products 511

Anh Dinh, MD, and Abdullah Alswied, MD, PhD

Providing Support for Off-Site Manufacturing	511
Planning and Onboarding of New Protocols	512
Documentation, Labeling, and Reporting	515
Cellular Starting Material Support	516
Final Cell Therapy Product Support	518
Future Directions	520
Conclusion	522
References	522
Appendix 35-1. Example Off-Site Manufactured Cell Therapy Protocol	
Initiation Intake Form	524

A P P E N D I C E S

Appendix 1. Template: User Functional Requirements Document	531
Appendix 2. Design Qualification Checklist	537
Appendix 3. Template: Risk Assessment Form	539
Appendix 4. Critical Equipment Selection Form	546
Appendix 5. Method for Selecting and Qualifying Equipment	548
Appendix 6. Installation, Operational, and Performance Qualification Form	555
Appendix 7. Sample Operational Qualification Form for LN2 Tank and Controller	560
Appendix 8. Suggested Quality Control and Maintenance Intervals for Equipment and Reagents	563
Appendix 9. Template for Annual Vendor Evaluation Questionnaire	565
Appendix 10. Template for Service Provider Qualification Survey	566
Appendix 11. Template for Supplier Approved Inventory Log	567
Appendix 12. CABP Alignment and Study Crosswalk	568
 Index	 577